Last reviewed · How we verify
Formulation E1 of L-PPDS — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Formulation E1 of L-PPDS (Formulation E1 of L-PPDS) — Mati Therapeutics Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Formulation E1 of L-PPDS TARGET | Formulation E1 of L-PPDS | Mati Therapeutics Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Formulation E1 of L-PPDS CI watch — RSS
- Formulation E1 of L-PPDS CI watch — Atom
- Formulation E1 of L-PPDS CI watch — JSON
- Formulation E1 of L-PPDS alone — RSS
Cite this brief
Drug Landscape (2026). Formulation E1 of L-PPDS — Competitive Intelligence Brief. https://druglandscape.com/ci/formulation-e1-of-l-ppds. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab